Figure 2.

COU254 does not improve outcome after experimental stroke in mice. Infarct size and functional outcome in COU254-treated mice and controls (vehicle) 24 h after 60 min transient middle cerebral artery occlusion (tMCAO). (a) (top) Representative 2,3,5-Triphenyltetrazoliumchloride (TTC)-stained coronal brain sections from the two animal groups. Ischemic infarctions appear white and regularly include the neocortex and basal ganglia as confirmed by hematoxylin and eosin (H&E) staining (bar represents 250 μm). (bottom) Infarct volumes on day 1 after tMCAO in COU254-treated mice and vehicle-treated controls as determined by planimetry (n = 10/group). Non-parametric Mann Whitney test, ns = not significant. (b) Neurological Bederson score and grip test score on day 1 after tMCAO in COU254-treated mice and vehicle-treated controls. In line with the results on infarct volumes, no significant functional differences became apparent between the treatment groups. Non-parametric Mann Whitney test, ns = not significant. (c) Accumulation of fibrin(ogen) in the infarcted (+) and contralateral (-) cortices of COU254-treated mice or vehicle-treated controls. Fibrinogen clotting 24 h after ischemia was analyzed by immunoblotting. Two representative immunoblots of each group are shown.